CCL23-CCR1趋化因子轴在上皮性卵巢癌疾病进展中的作用

Role of CCL23-CCR1 axis in the progression of epithelial ovarian cancer

目的研究CCL23-CCR1趋化因子轴在上皮性卵巢癌的疾病进展中的作用。方法首先对6例上皮性卵巢癌组患者及4例成年正常对照组血清中441种细胞因子行抗体芯片检测,筛选出差异表达蛋白CCL23;ELISA方法检测22例成年正常对照组血清及36例上皮性卵巢癌组患者血清中CCL23水平;qRT-PCR方法检测CCL23 mRNA在6例成年女性正常对照组和6例上皮性卵巢癌组组织中的表达;免疫组化方法分别对20例Ⅰ期、20例Ⅱ期,40例Ⅲ期、20例Ⅳ上皮性卵巢癌组原位病灶组织中趋化因子受体CCR1的表达进行检测。结果抗体芯片对血清中441种细胞因子进行比较,其中正常对照组血清CCL23表达水平(21924.20±2647.89)pg/ml,上皮性卵巢癌组患者血清CCL23水平(44902.00±2064.03)pg/ml,差异有统计学意义(t=-2.693,P=0.041);22例成年正常对照组血清CCL23表达水平(1157.80±457.40)pg/ml,36例上皮性卵巢癌组患者血清CCL23表达水平(1654.90±849.00)pg/ml,差异有统计学意义(t=-2.443,P=0.0188);上皮性卵巢癌组CCL23 mRNA表达较正常对照组CCL23 mRNA表达明显增高(t=-7.515,P=0.006)。上皮性卵巢癌组趋化因子CCL23受体CCR1免疫组化提示:CCR1在正常卵巢生发上皮(OSE)呈阴性表达,而在60例Ⅲ/Ⅳ期上皮性卵巢癌组原位病灶中阳性表达较40例Ⅰ~Ⅱ期卵巢癌明显增强。结论CCL23-CCR1趋化因子轴可能在上皮性卵巢癌疾病进展中发挥作用。

Objective To investigate the role of CCL23-CCR1 axis in progression of epithelial ovarian cancer.Methods Serum level of 441 kinds of chemokines was detected using RioBiotech antibody array in 6 patients with epithelial ovarian cancer and 4 normal adult females.Candidate biomarker was identified by SPSS analysis.We identified CCL23 as the differentially expressed protein.Serum levels of CCL23 in 22 normal adult females and 36 epithelial ovarian cancer patients were detected by ELISA.qRT-PCR was used to detect the expression of CCL23 mRNA in 6 normal adult ovarian tissues and 6 epithelial ovarian cancer tissues.Immunohistochemistry was used to detect the expression of CCR1 in situ lesions of 20 cases of StageⅠ,20 cases of StageⅡ,40 cases of StageⅢand 20 cases of StageⅣepithelial ovarian cancer.Results The concentrations of 441 cytokines were detected using antibody array,and CCL23 concentration was(21924.20±2647.89)pg/ml in normal control group while(44902.00±2064.03)pg/ml in patients with epithelial ovarian cancer(t=-2.693,P=0.041),the difference was statistically significant.Serum levels of CCL23 were(1157.80±457.40)pg/ml in 22 normal adult women while(1654.90±849.00)pg/ml in 36 cases of epithelial ovarian cancer patients(t=-0.2443,P=0.0188),the difference was statistically significant.The expression of CCL23 mRNA in epithelial ovarian cancer tissue was significantly higher than that in normal ovarian tissue(t=-7.515,P=0.006).The expression of CCR1 in situ lesions of epithelial ovarian cancer using immunohistochemistry demonstrated that ovarian surface epithelial(OSE)presented negative expression of CCR1.In contrast,the expression of CCR1 in 60 cases of stageⅢ/Ⅳwas higher than 40 cases of stageⅠ/Ⅱ.Conclusion CCL23-CCR1 axis may play a role in the progression of epithelial ovarian cancer.